<DOC>
	<DOC>NCT02610712</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission and inflammatory serum markers.</brief_summary>
	<brief_title>Clinical Trial of the Use of Ketamine in Treatment Resistant Depression</brief_title>
	<detailed_description>The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine (0.5 mg/kg) in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission measured by Magnetic Resonance Imaging Spectroscopy and inflammatory serum markers (IL-6, TNF-alpha).</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>TreatmentResistant Depression (Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies) Acceptance of participation via the informed consent Psychiatric comorbidity (except anxiety related disorders) Substance abuse or dependence in the previous 3 months Evidence of structural abnormalities in brain imaging Pregnancy Previous hypersensitivity to ketamine Heart failure or insufficiency Familial or personal history of psychosis Glaucoma Major neurological disease Uncontrolled systemic arterial hypertension MRI contraindications Nonacceptance of participation via informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>ketamine</keyword>
	<keyword>treatment-resistant</keyword>
	<keyword>depression</keyword>
	<keyword>spectroscopy</keyword>
	<keyword>neuroinflammation</keyword>
</DOC>